Sight Sciences Announces Multiple Presentations at the 2021

© 2021 Sight Sciences. All rights reserved.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Sight Sciences’ current expectations and various assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, Sight Sciences may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including the factors discussed under the caption “Risk Factors” in its registration statements on Form S-1, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Sight Sciences may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Sight Sciences’ views as of any date subsequent to the date of this press release

Related Keywords

United States ,American ,Adam Bleeker ,Interno Canaloplasty ,Markf Pyfer ,David Wirta ,Markj Gallardo ,Las Vegas ,Arkadiy Yadgarov ,Philip Taylor ,Shay Smith ,While The Company ,American Society Of Cataract ,Gilmartin Group ,While Sight Sciences ,Sight Sciences ,Nasdaq ,Sight Sciences Inc ,Surgical System ,Refractive Surgery ,Pacific Daylight Time ,Pseudophakic Eyes ,Minimally Invasive Glaucoma Surgery ,Mild Moderate Open Angle Glaucoma ,Prospective Multicenter Trial ,Blink Assisted Meibomian Gland Procedure ,Effective Treatment ,Dry Eye ,Multicenter Trial ,Intraocular Pressure ,Open Angle Glaucoma Undergoing ,Plus Trabeculotomy ,Cataract Surgery ,Prospective Clinical Trial Results ,Private Securities Litigation Reform Act ,Sight Science ,ஒன்றுபட்டது மாநிலங்களில் ,அமெரிக்கன் ,லாஸ் வேகாஸ் ,பிலிப் டெய்லர் ,ஷே ஸ்மித் ,போது தி நிறுவனம் ,அமெரிக்கன் சமூகம் ஆஃப் கண்புரை ,கில்மார்டின் குழு ,பார்வை அறிவியல் ,நாஸ்டாக் ,பார்வை அறிவியல் இன்க் ,அறுவை சிகிச்சை அமைப்பு ,ஒளிவிலகல் அறுவை சிகிச்சை ,பெஸிஃபிக் பகல் நேரம் ,குறைந்தபட்சம் ஆக்கிரமிப்பு கிள La கோமா அறுவை சிகிச்சை ,பயனுள்ள சிகிச்சை ,உலர்ந்த கண் ,கண்புரை அறுவை சிகிச்சை ,ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,